SCHEMBL4152308

SCHEMBL4152308

O=C(O)c1ccnc2[nH]c(-c3ccc(Cl)cc3Cl)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 7/20 0.45
TSHR P16473 1/20 0.45
CASP1 P29466 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GUSB P08236 1/20 0.44
KDM4C Q9H3R0 2/20 0.44
ALDH1A1 P00352 1/20 0.42
TP53 P04637 1/20 0.42
CHEK2 O96017 2/20 0.42
PIM1 P11309 2/20 0.42
PIM3 Q86V86 2/20 0.42
CDC7 O00311 1/20 0.42
PLK4 O00444 1/20 0.42
MAPK13 O15264 1/20 0.42
DAPK3 O43293 1/20 0.42
DYRK3 O43781 1/20 0.42
JAK2 O60674 1/20 0.42
ROCK2 O75116 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4148352 0.82 DHODH (0.49) KDM4CCHEK2KDRPBKDHODH
SCHEMBL4162893 0.80 PIN1 (0.53) GSK3BKDM4CDHODHKMO
SCHEMBL4629117 0.78 GSK3B (0.66) GSK3BTSHRCASP1SMN1; SMN2GUSB
SCHEMBL4145723 0.78 DHODH (0.54) GSK3BKDM4CALDH1A1DHODHKDM5A
SCHEMBL13778005 0.77 GSK3B (0.59) GSK3BALDH1A1L3MBTL1
SCHEMBL4152300 0.77 GSK3B (0.61) GSK3BSMN1; SMN2
SCHEMBL4153398 0.76 GSK3B (0.58) GSK3BTP53
SCHEMBL4147663 0.76 GSK3B (0.63) GSK3BSMN1; SMN2ALDH1A1
SCHEMBL4161528 0.75 GSK3B (0.54) GSK3BSMN1; SMN2
SCHEMBL4164533 0.75 GSK3B (0.59) GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885TSHR 4300/4885CASP1 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.